CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm
Investors who purchased the Company's securities between
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Corcept misled investors about the viability of its product candidate, relacorilant. Despite claiming relacorilant was "approaching approval," the Company knew that the FDA considered its clinical data was not adequate for approval. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Corcept, investors suffered damages.
Join the case to recover your losses
This press release may be considered
CONTACT:
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/cort-investors-have-opportunity-to-lead-corcept-therapeutics-incorporated-securities-fraud-lawsuit-with-the-schall-law-firm-302711862.html
SOURCE